Vitamin D and Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune synovitis driven by dysregulated T-cell and cytokine biology — the same immune pathways vitamin D modulates. Deficiency is more common in RA patients than in matched controls, and correlates inversely with disease activity scores.
Observational data
Meta-analyses consistently find lower 25(OH)D in RA patients vs controls, and higher Disease Activity Score (DAS28) in the lowest 25(OH)D quartiles. Whether this reflects causation, reverse causation (limited outdoor activity due to joint pain), or shared confounding (BMI, socioeconomic status) is not settled.
Prevention — the VITAL trial
The 25,000-person VITAL trial (2022 autoimmune substudy) reported cholecalciferol 2,000 IU/day for 5 years reduced incident autoimmune disease by 22% vs placebo; combined with omega-3 the effect was larger. RA was one of the diseases contributing to the composite endpoint. This is the strongest evidence to date that vitamin D supplementation might prevent RA in older adults.
Supplementation in established RA
- Small RCTs (Chandrashekara 2012; Salesi 2012) reported reduced DAS28 with adjunctive vitamin D 500–50,000 IU regimens.
- 2020 meta-analysis of 11 RCTs: modest improvement in pain scores and DAS28, most robust in patients starting deficient.
- Bone health is a separate reason — RA patients on chronic glucocorticoids need vitamin D + calcium for osteoporosis prevention regardless of the DAS28 evidence.
Practical guide
- Test 25(OH)D at diagnosis and annually.
- Correct to at least 30 ng/mL; some rheumatologists target 40–60 ng/mL.
- Standard dosing 1,000–2,000 IU/day; higher (up to 4,000 IU/day) if starting deficient.
- If on glucocorticoids, calcium 1,000–1,200 mg/day + vitamin D per ACR osteoporosis guidance.
- Vitamin D is an adjunct — methotrexate, sulfasalazine, hydroxychloroquine, biologics, and JAK inhibitors are the disease-modifying core.